

Laleh Majlessi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1748199/publications.pdf>

Version: 2024-02-01

26
papers

2,751
citations

331538

21
h-index

526166

27
g-index

32
all docs

32
docs citations

32
times ranked

2885
citing authors

#	ARTICLE	IF	CITATIONS
1	Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. <i>Nature Medicine</i> , 2003, 9, 533-539.	15.2	571
2	ESX secretion systems: mycobacterial evolution to counter host immunity. <i>Nature Reviews Microbiology</i> , 2016, 14, 677-691.	13.6	306
3	Dissection of ESAT-6 System 1 of <i>Mycobacterium tuberculosis</i> and Impact on Immunogenicity and Virulence. <i>Infection and Immunity</i> , 2006, 74, 88-98.	1.0	279
4	Control of <i>M. tuberculosis</i> ESAT-6 Secretion and Specific T Cell Recognition by PhoP. <i>PLoS Pathogens</i> , 2008, 4, e33.	2.1	234
5	Disruption of the ESX system of <i>Mycobacterium tuberculosis</i> causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. <i>Molecular Microbiology</i> , 2012, 83, 1195-1209.	1.2	178
6	Functional Analysis of Early Secreted Antigenic Target-6, the Dominant T-cell Antigen of <i>Mycobacterium tuberculosis</i> , Reveals Key Residues Involved in Secretion, Complex Formation, Virulence, and Immunogenicity. <i>Journal of Biological Chemistry</i> , 2005, 280, 33953-33959.	1.6	133
7	Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. <i>Cell Host and Microbe</i> , 2021, 29, 236-249.e6.	5.1	107
8	Strong Immunogenicity and Cross-Reactivity of <i>Mycobacterium tuberculosis</i> ESX-5 Type VII Secretion-Encoded PE-PPE Proteins Predicts Vaccine Potential. <i>Cell Host and Microbe</i> , 2012, 11, 352-363.	5.1	102
9	Recombinant BCG Expressing ESX-1 of <i>Mycobacterium marinum</i> Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. <i>Cell Reports</i> , 2017, 18, 2752-2765.	2.9	98
10	An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis. <i>Infection and Immunity</i> , 2006, 74, 2128-2137.	1.0	93
11	High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against <i>Mycobacterium tuberculosis</i> Infection. <i>Infection and Immunity</i> , 2006, 74, 3396-3407.	1.0	86
12	Release of mycobacterial antigens. <i>Immunological Reviews</i> , 2015, 264, 25-45.	2.8	77
13	Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. <i>Scientific Reports</i> , 2017, 7, 5390.	1.6	74
14	CD8 + -T-Cell Responses of <i>Mycobacterium</i> -Infected Mice to a Newly Identified Major Histocompatibility Complex Class I-Restricted Epitope Shared by Proteins of the ESAT-6 Family. <i>Infection and Immunity</i> , 2003, 71, 7173-7177.	1.0	52
15	CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary <i>Mycobacterium tuberculosis</i> Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005770.	2.1	50
16	Unexpected Genomic and Phenotypic Diversity of <i>Mycobacterium africanum</i> Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. <i>Genome Biology and Evolution</i> , 2018, 10, 1858-1874.	1.1	47
17	Intrinsic Antibacterial Activity of Nanoparticles Made of β -Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. <i>ACS Nano</i> , 2019, 13, 3992-4007.	7.3	42
18	RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection. <i>PLoS Pathogens</i> , 2018, 14, e1007139.	2.1	36

#	ARTICLE	IF	CITATIONS
19	Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. <i>Cell Reports</i> , 2018, 23, 1072-1084.	2.9	28
20	Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. <i>Cellular Microbiology</i> , 2016, 18, 1070-1077.	1.1	26
21	Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. <i>EMBO Molecular Medicine</i> , 2021, 13, e14459.	3.3	25
22	Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections. <i>Particle and Particle Systems Characterization</i> , 2019, 36, 1800360.	1.2	24
23	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. <i>Communications Biology</i> , 2021, 4, 713.	2.0	17
24	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. <i>Molecular Therapy</i> , 2022, 30, 2984-2997.	3.7	17
25	Use of lentiviral vectors in vaccination. <i>Expert Review of Vaccines</i> , 2021, 20, 1571-1586.	2.0	16
26	Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment. <i>Infection and Immunity</i> , 2015, 83, 3666-3674.	1.0	14